Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
PRNewswire (Wed, 8-Apr 6:59 AM ET)
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
PRNewswire (Tue, 10-Mar 6:59 AM ET)
PRNewswire (Thu, 19-Feb 5:31 PM ET)
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
PRNewswire (Wed, 18-Feb 6:59 AM ET)
Q32 Bio Announces $10.5 Million Registered Direct Offering
PRNewswire (Tue, 17-Feb 6:59 AM ET)
Market Chameleon (Mon, 1-Dec 4:51 AM ET)
Q32 Bio Secures $12 Million in Asset Sale, Extending Cash Runway and Refocusing Pipeline
Market Chameleon (Mon, 1-Dec 2:51 AM ET)
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Q32 Bio trades on the NASDAQ stock market under the symbol QTTB.
As of April 10, 2026, QTTB stock price climbed to $5.05 with 227,200 million shares trading.
QTTB has a beta of -1.84, meaning it tends to be less sensitive to market movements. QTTB has a correlation of 0.04 to the broad based SPY ETF.
QTTB has a market cap of $73.88 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that QTTB belongs to (by Net Assets): VTI, VXF, AVUV, DFAS, DFMC.
QTTB has outperformed the market in the last year with a return of +200.6%, while the SPY ETF gained +30.9%. In the last 3 month period, QTTB beat the market returning +40.3%, while SPY returned -1.8%. However, in the most recent 2 weeks QTTB has underperformed the stock market by returning -30.3%, while SPY returned +7.2%.
QTTB support price is $4.45 and resistance is $5.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QTTB shares will trade within this expected range on the day.
